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Abstract
Background:  Stanniocalcins (STCs) represent small glycoprotein hormones, found in all
vertebrates, which have been functionally implicated in Calcium homeostasis. However, recent data
from mammalian systems indicated that they may be also involved in embryogenesis, tumorigenesis
and in the context of the latter especially in angiogenesis. Human STC1 is a 247 amino acids protein
with a predicted molecular mass of 27 kDa, but preliminary data suggested its di- or
multimerization. The latter in conjunction with alternative splicing and/or post-translational
modification gives rise to forms described as STC50 and "big STC", which molecular weights range
from 56 to 135 kDa.
Results: In this study we performed a biochemical and structural analysis of STC1 with the aim of
obtaining low resolution structural information about the human STC1, since structural
information in this protein family is scarce. We expressed STC1 in both E. coli and insect cells using
the baculo virus system with a C-terminal 6 × His fusion tag. From the latter we obtained
reasonable amounts of soluble protein. Circular dichroism analysis showed STC1 as a well
structured protein with 52% of alpha-helical content. Mass spectroscopy analysis of the
recombinant protein allowed to assign the five intramolecular disulfide bridges as well as the
dimerization Cys202, thereby confirming the conservation of the disulfide pattern previously
described for fish STC1. SAXS data also clearly demonstrated that STC1 adopts a dimeric, slightly
elongated structure in solution.
Conclusion: Our data reveal the first low resolution, structural information for human STC1.
Theoretical predictions and circular dichroism spectroscopy both suggested that STC1 has a high
content of alpha-helices and SAXS experiments revealed that STC1 is a dimer of slightly elongated
shape in solution. The dimerization was confirmed by mass spectrometry as was the highly
conserved disulfide pattern, which is identical to that found in fish STC1.
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Background
Stanniocalcins (STCs) represent a small family of secreted
glycoprotein hormones consisting of STC1 and STC2 in
which amino acid sequences are highly conserved among
aquatic and terrestrial vertebrates [1-7]. However, the lack
of homology with other known proteins has hampered
the understanding of their functions. Initial evidence sug-
gested that mammalian STC1 would parallel the function
of fish STC1, which has been implicated in mineral home-
ostasis [8-10]. It is tempting to assume that the functions
of STC1 and STC2 overlap at least in part, since they share
high similarity in their primary amino acid sequence espe-
cially at the N-terminus and the pattern of cysteine resi-
dues is highly conserved [11].
However, there are also several differences between STC1
and STC2, including the fact that STC2 has 55 additional
amino acids, the majority of which are located at its C-ter-
minus [12-14]. Furthermore their expression patterns are
different[1,14-17] and STC2 is unable to displace STC1
from its putative receptor [18,19], indicating that both
molecules may have distinct receptors.
Although STC1 functions as an anti-hypercalcemic hor-
mone in fish [20-22], it is becoming increasingly clearer
that it may have expanded roles in mammals. Such
assumption is based on its wide expression pattern in
adult normal tissues[1,16,23-27], tumors [17,28,29] and
also during embryogenesis [30-35]. Further support for a
complex function of STC1 in mammals comes from stud-
ies that show its varying sub-cellular localizations [18,19]
and of a gain-of-function phenotype observed in trans-
genic mouse [36,37].
Relatively little is also known about STCs molecular struc-
ture. The human and mouse genomes encode a 247
amino acid STC1 protein [17,38]. The first 204 amino
acids show 92% sequence similarity to salmon STC1 and
include a conserved N-linked glycosylation site of the type
Asn-X-Thr/Ser (N-X-T/S) [17,39]. Compared to the fish
STC1 however, the last 43 residues at the C-terminus are
poorly conserved in human STC1 (and STC2), suggesting
that the main biological activity of the STCs is mediated
through its N-terminus [40,41].
In ancient fish, the last conserved cysteine residue in the
C-terminal of STC1, which is supposedly involved in its
dimerization, is replaced by arginine or histidine residues,
thereby giving rise to a strictly monomeric form of the
protein [42,43]. Although dimeric forms of STC1 have
been described [39,44,45], answers to the question of its
potential multimerization and modification to diverse
higher molecular weight forms under certain circum-
stances remain elusive.
STC1 however, seems to exist in two different forms, the
conventional dimeric 56 kDa form, consisting of two ~28
kDa monomers, also known as STC50, and a number of
higher molecular weight STC variants, collectively referred
to as "big STC" [19,25,46-49]. At least three molecular
weights: 84, 112, and 135 kDa have been described and
big STC1 has been reported to be expressed in adipocytes,
adrenocortical cells [47,48] and ovaries [19,25,49]. In
order to explain the increased mass of big STC1 it has been
suggested that either distinct post-translational modifica-
tions, including glycosylation [17,25] or phosphorylation
[50] occur in big STC or additional but yet uncharacter-
ized exons [48] are being employed. In agreement with
the latter, the monomeric form big STC1 is about ~10 kDa
larger than the theoretically predicted monomer. Another
possibility is the formation of tri- (84 kDa), tetra- (112
kDa) or even pentamers (140 kDa) of STC1, although in
this case obtained values only add up for the theoretically
predicted monomer (~28 kDa) but not for that observed
for the big STC monomer (~38 kDa). It is however note-
worthy that the 135-kDa variant of big STC1 found in
adrenocortical cells is resistant to chemical reduction, just
like STC50 from the mitochondrial matrix [48], thereby
suggesting the formation of a more stable and maybe
durable quaternary structure.
In this paper we present structural information about the
human STC1 protein. We expressed human STC1 in insect
cells using a bi-cistronic baculovirus construct. After affin-
ity purification we collected SAXS data for STC1 in solu-
tion. Data analyses are indicative of a dimeric protein in
solution. Furthermore, we were able to confirm the for-
mation of the conserved disulfide bridges, previously
reported in fish STC1, by mass spectrometry.
Results and Discussion
STC1 is predicted to be dimer and to possess a high 
content of alpha-helices
By analysing the human STC1 amino acid sequence using
six different secondary structure prediction databases, we
created a secondary structure consensus and scored it by
the number of times (one to six times) the predicted sec-
ondary structure element scored positive (Figure 1). Pre-
diction programs used were: PredictProtein/PROF [51],
PsiPRED [52], Predator [53], SOPMA [54], SSPro [55]
and JCFO [56].
In summary, the secondary structure analysis suggested
that about 34% of the amino acid sequence of STC1 may
form alpha-helices.
We further performed some predictions about ordered or
disordered regions within the sequence using FoldIndex
[57] and DisEMBL [58]) as well as GlobPlot [59] as a pre-BMC Structural Biology 2009, 9:57 http://www.biomedcentral.com/1472-6807/9/57
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dictor for more globular regions (Figure 1). The first two
programs both predicted that the pro-peptide region and
possibly the C-terminal region, this last one which con-
tains the Cys disulfide mediated dimerization region, to
be highly disorder or a region with high loop/turn con-
tent.
We analyzed and plotted (Figure 1) the conserved cysteine
residues as well as the experimentally determined
disulfide bridges from the salmon sequence determina-
tion [39], the signal peptide, pro-peptide and mature pro-
tein sequence as annotated at UniProtKB/Swiss-Prot
database (Swiss-Prot:P52823), and we also emphasize a
previously described nucleotide binding domain (NBD)
[60].
Additionally, some predictions about post-translational
modifications were performed and compared to pub-
lished experimental data. An N-glycosylation site which
had already been characterized for STC1 [17,41,61] was
also predicted by NetGlyc [62] (Figure 1)
For phosphorylation analysis we combined prediction
data from NetPhos [63] and NetPhosK [64] together with
in vitro phosphorylation data [50] to annotate tyrosine,
threonine and serine residues as putative phosphorylation
sites (Table 1). Most of the kinases that were found to
phosphorylate STC1 by the in vitro phophorylation
screening of Jellinek and coworkers were predicted by
both prediction programs (Table 1), except calmodulin-
dependent protein kinase (CaMPK-II) and casein kinase II
(CK2).
Analysis by PredictProtein/PHD Acc [51] revealed that
some of the residues such as S176 and T216, are predicted to
be exposed to the solvent and therefore more likely to suf-
Prediction of secondary structure and putative post-translational modification sites in the human STC1 amino acid sequence Figure 1
Prediction of secondary structure and putative post-translational modification sites in the human STC1 amino 
acid sequence. Linear representation of STC1-HT amino acid sequence with assignment of its different regions from N- to 
C-terminus: signal peptide (purple), pro-peptide (dark gray), mature protein (black), linker regions (light grey), TEV protease 
cleavage site (green) and 6 × His-tag (light blue). In the amino acid sequence, relevant residues are emphasized by the following 
color code: Cys: red, Asp predicted to be N-glycosylated: green, Lys predicted to be sumoylated: magenta, Ser, Thr e Tyr res-
idues predicted to be phosphorylated: blue. The conserved pattern of experimentally determined disulfide bridges from salmon 
STC1 is indicated by black horizontal brackets. Similarly the homo-dimerization Cys is indicated in black (dimer). Below the 
sequence there is a schematic representation of the predicted consensus secondary structure, obtained by six different predic-
tion programs (red: alpha helix, yellow: beta-sheet, green: coil regions, black: not assigned). The numbers below the secondary 
structure represent the score (16, indicating how many of the six programs predicted the respective secondary structure ele-
ment). Furthermore, in a second line, a prediction indicates whether a residue is exposed (e) or buried (b). At the bottom, pre-
dictions of three programs for ordered/disordered regions are given: FoldIndex (red: unfolded, green: folded), GlobPlot (green: 
globular, blue: disordered) and DisEMBL (blue: loops or coils, red: hot loops, green: missing coordinates).BMC Structural Biology 2009, 9:57 http://www.biomedcentral.com/1472-6807/9/57
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fer phosphorylation. Indeed, both residues refer to STC1
kinase sites found to be phosphorylated by Jellinek and
co-workers [50].
In order to screen for lysine residues predicted which may
be sumoylated in STC1 we used SUMOplot™ http://
www.abgent.com/tools/sumoplot and found three puta-
tive sumoylated residues (data not shown). The one hav-
ing the highest score is located at the end of the NBD and
the sumoylated residue (K83) is also predicted by Predict-
Protein/PHD Acc to be exposed to solvent. Most interest-
ingly, we found that STC1 interacted with the SUMO1
protein in a yeast two hybrid screen (unpublished data).
These data suggest that further experiments should be per-
formed to test if sumoylation of STC1 may occur in vivo,
in human cells.
Optimization of the expression and purification of STC1
Our first attempt to produce STC1 in E. coli using the HT-
STC1ΔNterm construct (Figure 2A) resulted in completely
insoluble expression (Figure 2B). Even splitting the pro-
tein in two halves using His-tag fusion did not make any
difference in solubility, since both parts still expressed in
insoluble form (data not shown). Only together with the
use of GST-tag (GST-C STC1) we could obtain some solu-
ble expression, however at very low amounts. The highest
rate of soluble expression could be obtained with GST-C
STC1 (Figure 2C and 2D).
On the other hand, using a modified bi-cistronic vector of
the baculovirus expression system we could obtain milli-
grams per liter of the soluble full-length his-tagged STC1
(STC1-HT) secreted into the media (Trindade et al.,
Table 1: Prediction of putative post-translational modification sites in human STC1.
Residue Modification Buried/Exposed
Residue[51]
Predictor (Score) Ref.
N62 N-glycosylation nd NetGlyc (0.61) [17,39,41,61]
K83 Sumoylation e SUMOplot™ (0.79) $
S95 PKC* phosphorylation b NetPhos (0.844)/NetPhosK (0.630) [50]
S115 PKC* phosphorylation nd NetPhos (0.788)/NetPhosK (0.722) [50]
PKA* phosphorylation nd NetPhos (0.788)/NetPhosK (0.841) [50]
RSK* phosphorylation nd NetPhos (0.788)/NetPhosK (0.601) nd
Y159 INSR* phosphorylation nd NetPhos (0.929)/NetPhosK (0.539) nd
S176 PKC* phosphorylation e NetPhos (0.938)/NetPhosK (0.630) [50]
T177 PKC* phosphorylation nd NetPhos (0.983)/NetPhosK (0.640) [50]
S181 PKA* phosphorylation nd NetPhos (0.993)/NetPhosK (0.647) [50]
T205 PKC* phosphorylation nd NetPhos (0.606)/NetPhosK (0.815) [50]
Cdc2* phosphorylation nd NetPhos (0.606)/NetPhosK (0.509) [50]
T216 PKG* phosphorylation e NetPhos (0.817)/NetPhosK (0.600) [50]
S235 GSK3* phosphorylation nd NetPhos (0.986)/NetPhosK (0.508) [50]
Cdk5* phosphorylation nd NetPhos (0.986)/NetPhosK (0.551) [50]
S237 PKC* phosphorylation nd NetPhos (0.531)/NetPhosK (0.647) [50]
T242 PKG* phosphorylation nd NetPhos (0.523)/NetPhosK (0.693) [50]
High score predictions of glycosylation, sumoylation and phosphorylation on STC1 sequence are presented. Predicted modifications within the pro-
peptide region were excluded. Putative phosphorylated residues shown here are only those that were both predicted with the highest scores by 
the NetPhos server and additionally were predicted by NetPhosK, which suggests a specific kinase for the same site. References are related to 
additional experimental support for the predicted modification, if available. * indicate kinase as predicted by NetPhosK [protein kinase A C or G 
(PKA; PKC and PKG); 90-kDa Ribosomal S6 Kinase (pp90RSK or RSK); Insulin receptor (INSR); cell division cycle 2 (cdc2 or p34 protein kinase); 
ciclin dependent kinase 5 (cdk5); Glycogen synthase kinase 3 (GSK3)]; e = exposed residue, b = buried residue, nd = not determined; $ = 
unpublished data.BMC Structural Biology 2009, 9:57 http://www.biomedcentral.com/1472-6807/9/57
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unpublished data). The amount of virus and of infected
cells could be easily optimized, since the recombinant bi-
cistronic baculo virus promotes production of endog-
enous GFP protein, turning infected cells green.
Purification was obtained by a three step chromatography
of the media: cation exchange followed by metal-affinity
and size exclusion chromatographies (Figure 2E). Several
milligrams of protein were routinely obtained per liter of
culture supernatant and the obtained protein was used for
subsequent experiments.
Confirmation of disulfide bonds by mass-spectrometry
By analysing the recombinant human STC1-HT produced
in the baculovirus system by ESI/Q-TOF analysis we were
able to identify and assign the peptides that resulted from
enzymatic digestion either with trypsin or chymotrypsin
in the oxidized and/or reduced forms (Table 2, [see Addi-
tional file 1, 2 and 3]). In brief, the data show the exist-
ence of peptides having mass compatible with the
presence of the previously predicted disulfide bonds for
the salmon STC1. In Table 2, the first column gives the
disulfide bridge in question and the last four columns give
respectively the expected and experimentally determined
peptide masses. In conclusion, all disulfide bridges except
for one could be directly demonstrated. Still Cys45-Cys59
could be evidenced indirectly, since the mass of the pep-
tide shown in line one of Table 2 is compatible with this
interpretation. Furthermore, after chemical digestion with
formic acid, Cys202 could be unambiguously assigned as
the Cys residue responsible for the dimerization of
human STC1 (Table 2, [see Additional file 1, 2 and 3]).
Analysis of secondary structure
Such a relatively high content predicted by in silico analy-
sis (Figure 1) is supposed to be readily detected by circular
dichroism spectroscopy of the protein, so the content of
secondary structure elements in recombinant human
STC1-HT was determined by circular dichroism spectros-
copy. Figure 3 shows the spectrum of purified STC1
Large scale STC1 expression in E. coli and in insect cells and its purification Figure 2
Large scale STC1 expression in E. coli and in insect cells and its purification. (A) Tested STC constructs (from top 
to bottom): an amino-6 × His tagged STC1 without the N-terminal portion which includes the signal peptide (HT-
STC1ΔNterm), an amino-GST tagged C-terminal fragment of STC1 (GST-C STC1) and a full length carboxy-6 × His tagged 
STC1 (STC1-HT). At the right side of each construct is shown the amino acid residues from native STC1 present on that con-
struct. (B) Expression test of HT-STC1ΔNterm. Coomassie-blue stained SDS-PAGE of soluble (S) and insoluble (I) fractions 
expressed in BL21DE3 non-induced (NI) or induced for indicated periods with 0.5 mM IPTG in LB at 37°C. (C) GST-C STC1 
purification by affinity chromatography using glutathione sepharose beads. Coomassie-blue stained SDS-PAGE of insoluble (I), 
soluble (S), flow-through (FT), wash (W) and elution (E1-E3) fractions. (D) Western blot anti-GST of E2 fraction of purification 
shown in C. Black arrow heads at right indicate expected recombinant protein size and red arrow head indicates un-fused GST 
protein. (E) Expression and purification of STC1-HT from insect cells (using the baculo virus system): Coomassi-blue stained 
SDS-PAGE of peak-fractions after cation exchange, metal affinity and Size Exclusion chromatography. Arrow head indicates 
expected size of recombinant expressed protein. Invitrogen Bench Marker protein ladder (M).BMC Structural Biology 2009, 9:57 http://www.biomedcentral.com/1472-6807/9/57
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recorded at 4°C. Purified protein presents negative ellip-
ticity in the near-UV, with minima at 208 (-17.2 × 103 deg
cm2 dmol-1) and 222 nm (-12.8 × 103 deg cm2 dmol-1).
Deconvolution of the CD spectrum lead to the following
estimation of the content of secondary structural ele-
ments: ~52% of α-helices, ~19% of β-sheets strands,
~11% of turns and ~18% unordered (NRMSD = 0,009)
using the CDSSTR algorithm on the Dichroweb web
server [65]. Consensus predictions of secondary structures
shown in Figure 1 give values of about 37% of helix, 2.5%
of strands and 65.5% of other structures (37% of coils and
28.5% of non-determined). Secondary structural predic-
tors like PSIPRED are based on neural networks trained
on known folds, and thus tend routinely to underestima-
tion of the true helical and strand content, due to the fact
that the reference databases are not complete. A more crit-
ical issue is the fact that no other protein of the family of
STCs has its structure resolved. In conclusion both the pre-
diction and the experimentally determined data are in rea-
sonable agreement, since they demonstrate a relatively
high content of alpha-helices in human STC1.
STC1 is a compact, slightly ellipsoidal dimer in solution
Dynamic Light Scattering (DLS) data of the recombinant
STC1 sample showed a single and narrow peak, which is
an indicative of a monodisperse solution of dimers.
The corrected and normalized experimental SAXS data are
shown in Figure 4A, together with the GNOM curve fit-
ting. The Guinier region providing an Rg value of 27.4 ±
0.8 Å is shown in the inset. The p(r) function resulting
from these calculations is shown in Figure 4B, with an
inset showing the Kratky representation of the intensity
curve. The Kratky plot indicates a slightly compact confor-
mation for STC1 in solution. The maximum dimension
(Dmax) value obtained was 90 Å and the Rg value, calcu-
lated from the p(r) function, was 27.8 ± 0.4 Å, in close
agreement with that calculated from the Guinier approxi-
Table 2: Identification of signature peptide sequences of STC1-HT for the assignment of the intra- and intermolecular disulfide bonds.
Mass
Disulfide Bond Sequence of peptides Protease Theoretical Observed (Expected)
[M+2H] [M+3H] [M+4H]
C45-C59; C54-C74; C65-C114 C45LNSAL...IDCK75
C114STFQR119
Trypsin 3981.51 996.22
(996.38)
C54-C74 Q51VGCGAFA57
D72ICKSF77
Chymotrypsin 1389.61 695.95
(695.81)
464.24
(464.21)
C65-C114 E61NSTC...GMY71
A110IRRCSTF117
Chymotrypsin 2184.89 729.36
(729.30)
547.26
(547.23)
C98-C128 C98IANGVTSK106
M120IAE...CYSK131
Trypsin 2318.06 773.73
(773.69)
580.56
(580.52)
C98-C128 K97CIA...SKVF108
Q118RMIA...EECY129
Chymotrypsin 2761.32 921.17
(921.45)
691.14
(691.34)
C135-C170 L132NVCSIAK139
S166LLEC...TIR179
Trypsin 2424.19 809.12
(809.07)
607.08
(607.05)
Mass
Disulfide Bond Sequence of peptides Chemical Reagent Theoretical Observed (Expected)
[M+H]
C202-C202*D 200HCAQTHPRA209
D200HCAQTHPRA209
Formic acid 2266.98 2268.11
(2267.99)
Samples were digested by trypsin or chymotrypsin with or without dithiotreitol and iodoacetamide, separated by UPLC and analyzed by ESI-QTOF; 
or digested with formic acid and analyzed by MALDI-QTOF. The presented mass is the monoisotopic. Dimer disulphide bond is indicated by 
asterisk (*) [see Additional file 1, 2 and 3].BMC Structural Biology 2009, 9:57 http://www.biomedcentral.com/1472-6807/9/57
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mation. As it can be noted from the p(r) function shape,
STC1 has a slightly elongated shape.
Using BSA as a reference sample, the molecular mass for
STC1 HT, estimated from the SAXS data, was ~54 kDa.
This value is in agreement with the prediction of the pro-
tein being a dimer, since the theoretically calculated
molecular mass of the monomer was ~27 kDa (calculated
from the amino acids sequence using ProtParam tool
[66]).
The dimerization was also confirmed both by mass spec-
trometry (see above) and by size exclusion chromatogra-
phy (data not shown).
Low resolution ab initio SAXS-based models for STC1
The low resolution models for STC1 are presented in fig-
ure 5. Those models were derived from the experimental
SAXS data imposing a 2 point symmetry constraint (P2).
Additional models calculated without symmetry con-
straint (P1) presented very similar molecular envelopes.
The calculated values of the Normalized Spatial Discrep-
ancy (NSD), which is an indicator of the difference
between models, gave values of ~0.6 for P1 vs. P2 DAM-
MIN models and ~0.8 for P1 vs. P2 GASBOR models, sug-
gesting a low discrepancy. In view of this result, all model
calculations were performed using a 2 point symmetry
constraint. After several runs performed with the program
DAMMIN, the averaged and filtered (with the corrected
excluded volume) dummy atom model for STC1 is shown
in Figure 5A. The NSD values for the set of 10 models
ranged from 0.60 to 0.69, which are considered reasona-
ble values [67]. This low resolution model shows the
expected elongated shape for the protein dimer. The most
typical and recurrent dummy residue model resulting from
the calculation with the program GASBOR is shown in
Figure 5B. The NSD values for this set of 10 calculations
ranged from 0.82 to 0.87, which are also quite reasonable.
This last approach produced an improved molecular
envelope for STC1. Comparing the results, both molecu-
lar envelopes obtained for STC1 presented a similar shape
and confirmed the elongated conformation for the dimer.
Conclusion
Our data provided the first low resolution 3D structure of
human STC1 protein in solution. SAXS experiments indi-
cated that STC1 forms a dimer of slightly elongated shape
in solution. Circular dichroism spectroscopy confirmed
the prediction of a high alpha-helical content and we
could also confirm by mass spectrometry the highly con-
served disulfide pattern, previously described in fish
STC1[39]. Disulfide bonds are formed between the same
10 of the 11 conserved Cys, in the same fashion, leaving
the C-terminal Cys 202 free to engage in dimer formation.
None of our data explain the composition or structure of
"bigSTC1" previously reported to appear in certain tissues
[19,25,46-49]. Indeed, our results only show the forma-
tion of dimers (STC50), by several independent methods.
In human cells however, we may have additional contri-
butions from possible post-translational modifications or
alternative splice variants of the pre-mRNA encoding
STC1, which may contribute to the appearance of the
higher molecular weight forms. Further experiments are
required to characterize big STC1 at the molecular level
and point out its differences with the canonical dimeric
human STC1.
Methods
In silico sequence analysis
We analyzed the human STC1 sequence as a query in six
different secondary structure prediction databases (Pre-
dictProtein/PROF [51], PsiPRED [52], Predator [53],
SOPMA [54], SSPro [55] and JCFO [56]). We also per-
formed some predictions about ordered or disordered
regions within the sequence using FoldIndex [57] and
DisEMBL [58]) as well as GlobPlot [59], a predictor for
globular regions. Additionally, some predictions about
post-translational modifications were done and com-
pared to previous published data. N-glycosylation sites
were predicted by NetGlyc [62]. For phosphorylation we
combined prediction data from NetPhos [63] and Net-
PhosK [64]. With PredictProtein/PHD Acc [51], we pre-
dicted whether residues are exposed to solvent or buried.
Circular Dichroism spectra of STC1-HT and deconvolution Figure 3
Circular Dichroism spectra of STC1-HT and decon-
volution. Graph of the wavelength plotted against the mean 
residue elipticity of a sample at 5,5 mM in 10 mM MES; 33,3 
mM NaCl pH 6,5 at 4°C. Data were deconvoluted with the 
CDSSTR program on the Dichroweb server. Note the two 
minima at 208 and 222 nm, which are typical of alpha-helix 
containing proteins. Reconstructed data are those derived 
from the Dichroweb database.BMC Structural Biology 2009, 9:57 http://www.biomedcentral.com/1472-6807/9/57
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Finally, in order to screen for lysine residues predicted
which may be sumoylated in STC1 we used SUMOplot™
http://www.abgent.com/tools/sumoplot.
Cloning of STC1 cDNA
Full-length STC1 (Genbank NM_003155) gene was
amplified from normal bone marrow stromal cells using
primers STC1 F (5' aaggatccAGAATGCTCCAAAACTCAGC
3') and STC1 R (5' ccgaattCCTCTCCCTGGTTATGCAC 3')
and cloned into vector pGEM resulting in plasmid pGEM-
STC1. In order to obtain all constructs we used pGEM-
STC1 as template and cloned PCR amplified products into
pGEM plasmid: for pGEM-STC1 ΔNterm(STC1 lacking the
first 22 amino acids) we used primers STC1 ΔNterm F (5'
aaggatccCAGAATGACTCTGTGAGCCC 3') and STC1 R;
for pGEM-STC1 full without stop (STC1 without stop-
codon) we used primers STC1 F and STC1 no stop R (5'
acaagcttCCTCTCCCTGGTaATGCAC 3'); for pGEM-
CSTC1 (C terminal of STC1 consisting of residues from
129 to 247) were used primers CSTC1 F (5' ggatccTACAG-
CAAGCTGAATGTGTG 3') and CSTC1 R (5' gaattcTTAT-
GCACTCTCATGGGATG 3'). Capital letters indicate
sequence identical to STC1 cDNA, small caps letters indi-
cate sequence non-identical to template. All pGEM con-
structs were verified by DNA sequencing in order to
ascertain the correct nucleotide sequence. pGEM-STC1
ΔNterm and pGEM-CSTC1 were digested with BamHI and
EcoRI and the resulting inserts were cloned into pET28a-
His-Tev or pET28a-GST-Tev [68] previously digested with
the same endonucleases. This resulted in pET-HT-STC1
ΔNterm, pET-HT-CSTC1, and the pET-GST-CSTC1 con-
structs. pGEM-STC1 full without stop was digested with
BamHI and HindIII and cloned into a pFastBAC
Dual+EGFP (pFBDg), which had the EGFP cDNA cloned
under p10 promoter, digested with same endonucleases
to insert STC1 under polyhedron promoter. Subsequently
a pair of oligonucleotides (5'AGCTTGGAAAACCTGTATT
TTCAGGGCCATCACCATCACCATCACCGG 3' and 5'AG
CTCCGGTGATGGTGATGGTGATCGCCCTGAAAATA CA
GGTTTTCCA 3') previously annealed was added to gener-
ate a linker consisting of a TEV protease site and a 6 × His-
tag (HT) at the C-terminal, resulting in the pFBDg-STC1-
HT construct. Other constructs mentioned in the text were
generated by using the same methodology.
Expression and purification of STC1
Production of the recombinant 6 × His- or GST-STC1
fusion constructs in E. coli BL21 strain and subsequent
purification trials were performed as described previously
for other recombinant proteins [69,70].
High Five™ (Invitrogen) cells were adapted to grow in sus-
pension culture in Express Five™ serum free media
(Gibco) supplemented with 20 mM L-Glutamine (Gibco)
and 1× PenStrep (Gibco). The stock cell culture was main-
tained and passaged in a 28°C incubator (ThermoForma).
For STC1-HT production High Five cells were scaled up
from the stock culture to a cell density of 1 × 106 in two 2L
Erlenmeyer flasks containing 500 mL each and incubated
at a shaker at 26°C at 140 rpm. Twelve hours post inocu-
lation, the cells were infected with the recombinant bac-
ulo virus, at a multiplicity of infection (m.o.i.) between 3
Experimental Small Angle X-ray Scattering (SAXS) curves for recombinant STC1-HT protein Figure 4
Experimental Small Angle X-ray Scattering (SAXS) curves for recombinant STC1-HT protein. (A) Experimental 
scattering curve of STC1-HT (open circles) and the theoretical fitting (solid line) by using the program GNOM. Inset: Guinier 
Region. (B) Pair-distance distribution function p(r). Inset: Kratky representation of the intensity curve.BMC Structural Biology 2009, 9:57 http://www.biomedcentral.com/1472-6807/9/57
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and 4 plaque-forming unit (pfu) per cell. Baculovirus-
infected High Five culture media were harvested after 48
hours post-infection by centrifugation at 500 × g for five
minutes and cell-free supernatant containing secreted
STC1-HT was used for purification. To the baculovirus
supernatant a 1 M MES stock solution was added to bring
the solution to a final concentration of 50 mM MES pH
6.5 (IEX buffer). The solution was filtered through a 0.45
μm MCE membrane (Fisherbrand) and loaded onto a
water-jacketed chilled (4°C) XK26/20 (Pharmacia Bio-
tech/GE) column previously packed with SP Sepharose FF
(Pharmacia Biotech/GE) at a flow rate of 1 mL/min using
a peristaltic pump (Biologic LP  Biorad). Column was
transferred to an ÄKTA FPLC system (GE) for protein elu-
tion using a 01 M gradient of NaCl in IEX buffer. Fractions
eluted from a conductivity of 30 mS/cm onward, con-
tained most of stanniocalcin 1 protein and were pooled.
This pool was directly loaded onto a pre-packed HisTrap
crude FF 5 mL (GE) column, equilibrated with 50 mM
MES pH 6.5, 500 mM NaCl (affinity buffer). After injec-
tion of sample the column was washed with six column
volume (CV) of affinity buffer, with three CV of affinity
buffer containing 250 mM Imidazole and finally with
four CV of affinity buffer containing 1 M Imidazole. This
last pool of fractions containing most of stanniocalcin
was concentrated using an Amicon Ultra-15 Centrifugal
Filter Unit with Ultracel-10 membrane of 5,000 NMWL
(Millipore) on a swing-rotor at 4°C and then 500 μL
applied to a water-jacketed chilled (4°C) Superdex 200 pg
16/60 (GE) column, pre-equilibrated with 60 mM MES
600 mM NaCl pH 6.5 (SizeEx buffer) with a flow rate of
0.5 mL/min. Protein eluted at a single peak between 70
and 80 mL was analyzed by SDS-PAGE, pooled, concen-
trated and kept in SizeEx buffer at 4°C. The purity of the
recombinant STC1 protein was confirmed by mass spec-
trometry analysis, which resulted in the exclusive identifi-
cation of STC1 peptides (data not shown).
Disulfide bond and molecular mass analysis
Samples digested by trypsin or chymotrypsin, treated or
not with dithiotreitol and iodoacetamide, were analyzed
by using ultra-performance liquid chromatography
(UPLC NanoAcquity, Waters) coupled with eletrospray
ionization quadrupole time-of-flight tandem mass spec-
trometer (ESI-QTOF Ultima, Waters/Micromass). Sam-
ples chemically digested by formic acid [71], treated or
not with dithiotreitol and iodoacetamide, were analyzed
using MALDI-QTOF (Q-Tof Premier, Waters/Micromass).
Data were analyzed by the MassLynx software package.
Circular Dischroism
Circular dichroism spectra were recorded at 4°C between
190 and 260 nm on a J-810 Jasco spectropolarimeter
equipped with a Peltier-type system PFD 425S using a
quartz cuvette of 10 mm path length, with a 50 nm/min
scanning speed and a band-width of 0.5 nm. Twenty spec-
tra of purified STC1-HT at 2.77 μM in dilution buffer (10
mM MES 33.3 mM NaCl pH6.5) were averaged and cor-
rected from the baseline for buffer solvent contribution.
Experimental data were analyzed using CDSSTR on
Dychroweb web server [65].
Small Angle X-Ray Scattering and Analysis
Before the analysis, the sample was inspected by dynamic
light scattering (DLS) to test the monodispersity of the
solution. After that, the sample was centrifuged at 20.000
× g for 30 min at 4°C to remove any possible aggregates.
The small-angle X-ray scattering experiments were per-
formed at the D02A-SAXS2 beam line at LNLS. The meas-
urements were performed at 4°C under temperature-
controlled conditions (via water circulation) using a 1
mm path length cell with mica windows and a monochro-
matic X-ray beam (wavelength of λ = 1.488 Å). The X-ray
patterns were recorded using a two-dimensional position-
sensitive MARCCD detector and a sample-to-detector dis-
tance of 902 mm, resulting in a useful scattering vector
range of 0.015Å-1 < q < 0.25 Å-1, where q is the magnitude
of the q-vector defined by q = (4π/λ)sinθ (2θ is the scat-
tering angle). Three successive frames of 300 seconds each
and one frame of 30 minutes were recorded. The measure-
ments were performed with two different concentrations
for the sample in MES buffer (60 mM MES 200 mM NaCl
pH 6.5): 0.15 and 0.18 mg/mL, both measured using the
BCA™ Protein Assay Kit (Pierce). The buffer scattering
curves were recorded keeping the same conditions used
for the sample. The intensity curves were individually cor-
rected for detector response and scaled by the incident
beam intensity and sample absorption. Subsequently,
buffer scattering was subtracted from the corresponding
Low resolution ab initio model of STC1-HT derived from  SAXS data Figure 5
Low resolution ab initio model of STC1-HT derived 
from SAXS data. (A) Three selected views of the average 
and filtered dummy atoms model (DAMMIN). (B) Three 
selected views of the dummy residues model (GASBOR). The 
models were displayed by the PyMOL program [80].BMC Structural Biology 2009, 9:57 http://www.biomedcentral.com/1472-6807/9/57
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sample scattering. The resulting curves were inspected for
radiation-induced damage, but no such effect was
observed. After scaling the curves for concentration, no
concentration effect was observed. A 10 mg/ml BSA (66
kDa) solution in the same sample buffer was used as
molecular mass standard sample to estimated the molec-
ular mass of STC1-HT. This value was inferred from the
ratio of the extrapolated values of the intensity at the ori-
gin, I(0), from both sample and BSA solutions scattering
[72,73].
The first analysis was the evaluation of the radius of gyra-
tion (Rg) using the Guinier approximation:
 for qRg < 1 [74-76]. The Rg was
also calculated from the pair distance distribution func-
tion, p(r), which was obtained by indirect Fourier trans-
form of the intensity curve using the program GNOM
[77]. The p(r) function also provided the maximum
dimension (Dmax) of the molecule, Moreover, a Kratky
representation [75,76] of the intensity curve (q2I(q) vs. q)
was used to analyze the compactness of the protein con-
formation.
Ab initio SAXS-based modeling
The low resolution models for STC1 were restored from
the SAXS intensity curves using two different approaches.
In the first one, implemented by the program DAMMIN
[78], the protein was represented as an assembly of
densely packed spherical beads (dummy atoms). Using
simulated annealing, the program starts from a random
configuration of beads and searches for a configuration
that best fits the experimental pattern. Ten calculations
were performed and the normalized spatial discrepancies
(NSD) [67] values among them were evaluated using the
DAMAVER suite. When the NSD values are not so differ-
ent, an averaged and filtered model structure (with the
correct excluded volume) emerges from this calculation.
The second approach, in which generally a better model is
obtained, was implemented using the program GASBOR
[79]. In this approach, the protein is represented as a
chain of dummy residues (DRs). The number of DRs is usu-
ally known a priori from the protein amino acid sequence.
Starting from a randomly distributed gas of DRs inside a
spherical volume of diameter Dmax, a simulated annealing
routine was employed to find a chain-compatible spatial
distribution of DRs which fit the experimental scattering
pattern. Ten different calculations were also performed
and the NSD values were evaluated. In this case, there is
no advantage in obtaining an average model because the
GASBOR program uses a predefined number of DRs,
which makes the average routine little effective in achiev-
ing an improvement of the model resolution. So, we
present the most typical model (with the lowest NSD
value). In both approaches, the models calculated with 2
point-symmetry constraint were very similar to those cal-
culated without these constraints. For this reason, the
results presented here are from the calculation with 2
point-symmetry constraint. Both models were displayed
by the PyMOL program [80].
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